No Data
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) CEO Fei Gao, the Company's Largest Shareholder Sees 7.2% Reduction in Holdings Value
Aotai Bio (688606.SH): A subsidiary plans to invest no less than 0.3 billion yuan to build a project for an annual output of 0.2 billion diagnostic reagents and electronic instruments.
On March 20, Gelonghui reported that Aotai Biotechnology (688606.SH) announced that its wholly-owned subsidiary, Fantian Biotechnology Co., Ltd. (hereinafter referred to as "Fantian Biotechnology"), plans to invest 10 million USD in its wholly-owned subsidiary, Fanling Biotechnology (Hangzhou) Co., Ltd. (hereinafter referred to as "Fanling Biotechnology"), with its own funds. It will enter into an investment attraction agreement with the Hangzhou Linping Economic and Technological Development Zone Management Committee through Fanling Biotechnology, responsible for land bidding and factory construction, investing in the project of producing annual output of 0.2 billion diagnostic reagents and electronic instruments, with a total project investment of no less than 0.3 billion RMB. This matter does not belong to the related party transactions.
Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Prospects Need A Boost To Lift Shares
Aotai Biotech: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Shareholder Xu Jianming of Aotai Biology (688606.SH) plans to Shareholding no more than 0.5 million shares.
Aotai Biotechnology (688606.SH) announced that shareholder Xu Jianming intends to implement this Shareholding reduction plan due to personal financial needs...
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?